City
Epaper

'Nobel winning mRNA tech publicly funded, not by pharma'

By IANS | Updated: October 2, 2023 19:40 IST

New Delhi, Oct 2 The mRNA vaccine technology against Covid-19, which on Monday received the 2023 Nobel for ...

Open in App

New Delhi, Oct 2 The mRNA vaccine technology against Covid-19, which on Monday received the 2023 Nobel for Medicine was publicly funded and not by pharma giants, said the People's Vaccine Alliance.

The People's Vaccine Alliance is a coalition of organisations and activists working together towards equitable access to medical technologies that help to prevent and respond to Covid and future pandemics.

Katalin Kariko and Drew Weissman were jointly awarded the 2023 Nobel Prize in Physiology or Medicine "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against Covid-19", said the Nobel Assembly at the Karolinska Institutet in a statement.

Their groundbreaking findings have fundamentally changed the understanding of how mRNA interacts with our immune system, the Nobel committee said.

The umbrella group of NGOs hailed public funding, which it said "delivers incredible medical advances", even as pharma giants refused to share vaccine technology, as well as test kits and other diagnostics to low-income countries during the pandemic.

"The award challenges the claim that it was solely big pharmaceutical companies who saved the world from Covid-19," said Mohga Kamal-Yanni, Policy Co-Lead for the People's Vaccine Alliance, in a statement.

"Just like the Oxford-AstraZeneca vaccine, Kariko and Weissman's groundbreaking work on mRNA vaccines received a huge amount of public funding."

Kamal-Yanni also advised governments preparing for the next pandemic to prioritise on public funding as drugmakers will not share vaccines with the world.

"Pharmaceutical companies have refused to share mRNA technologies with developers and researchers in developing countries. Fortunately, Weissman is helping a WHO-backed mRNA programme which aims to develop mRNA technology in lower-income countries, even while pharmaceutical companies refuse to share their know-how," Kamal-Yanni said.

"As governments discuss how to prepare for the next pandemic, they should learn from the story of mRNA. Public funding delivers incredible medical advances and that should be a priority for all countries, but pharmaceutical companies cannot be trusted to share technology with the world."

Disclaimer: This post has been auto-published from an agency feed without any modifications to the text and has not been reviewed by an editor

Open in App

Related Stories

International"Hands, feet of deceased had melted": Students recall horror after Bangladesh Air Force plane crashes into Dhaka school

CricketKranti Goud six wicket haul, Harmanpreet's century seals series for India 2-1 against England

MumbaiMumbai Local Train Hit by Landslide Debris Near Kasara; Commuter Injured

EntertainmentNetflix announces documentary about Jussie Smollett, his 2019 hate crime hoax

International"India came to our aid at a time of need": Ex-Maldivian FM Dunya Maumoon

International Realted Stories

InternationalIndia submits TEPA ratification document to Norway, paves way for EFTA trade pact

InternationalIndia to send burn-specialist team to Dhaka to treat air crash victims: MEA

International"Scrubbing work is underway": Vikram Doraiswami on FTA ahead of PM Modi's UK visit

InternationalBoeing projects global demand for 2.4 million aviation personnel by 2044

InternationalPM's visit to Maldives comes amid "hard-won understanding" after a "small patch of misunderstanding": Former Diplomat